



TIOTROPIUM inhalation (Spiriva Respimat[®] ▼) for asthma in children and young people

G
R
E
Y

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of TIOTROPIUM inhalation (Spiriva Respimat[®] ▼) for asthma in children and young people <18 years of age.

- > This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.
- > Tiotropium inhalation (Spiriva Respimat[®] ▼) is licensed for asthma in people aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.

Guidance on inhaler choice in asthma in children and young people <18 years of age may be found in [Pan Mersey Asthma treatment guideline for GP's and practice nurses - Children 5 years old and over](#).

References

1. Summary of Product Characteristics. [Spiriva Respimat](#). Accessed 21 May 2018.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.